Status:
UNKNOWN
A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Idiopathic Retroperitoneal Fibrosis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This prospective, interventional, controlled study is aimed to evaluate the efficacy and safety of cyclophosphamide in the treatment of idiopathic retroperitoneal fibrosis, which refers to the chronic...
Detailed Description
Idiopathic retroperitoneal fibrosis is a chronic disease that requires treatment for a few years. Patients with this disease respond well to glucocorticoid therapy, so you need to take glucocorticoid ...
Eligibility Criteria
Inclusion
- age 18-75 diagnosed as IRPF. The diagnosis of idiopathic retroperitoneal fibrosis is based on the following aspects :(1) the swelling of retroperitoneal tissue , which seems neoplastic; (2) A large number of lymphocytes proliferated and infiltrated in the affected tissues and organs, and tissues showed inflammation, fibrosis and sclerosis, in which IgG4-positive cells accounted for less than 50% of plasma cells; (3) Increased inflammatory markers, such as ESR and CRP; (4) Good response to glucocorticoid therapy.
Exclusion
- malignancy retroperitoneal fibrosis secondary to other diseases or drugs or abdominal surgeries.
Key Trial Info
Start Date :
January 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 10 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04762810
Start Date
January 3 2020
End Date
February 10 2023
Last Update
March 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100032